Foghorn Therapeutics (FHTX) Price & Analysis

Compare

428 Followers

FHTX Stock Chart & Stats

$5.40

$0.09(1.92%)

At close: Jan 08 4:00 PM EST

$5.40

$0.09(1.92%)

Day’s Range― - ―

52-Week Range$2.94 - $6.79

Previous CloseN/A

Volume24.60K

Average Volume (3M)157.41K

Market Cap

$305.38M

Enterprise Value$119.78M

Total Cash (Recent Filing)$180.28M

Total Debt (Recent Filing)$22.53M

Price to Earnings (P/E)―

Beta1.93

Next Earnings

Mar 05, 2026

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding56,551,290

10 Day Avg. Volume207,613

30 Day Avg. Volume157,412

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)-5.69

Price to Sales (P/S)11.46

P/FCF Ratio-2.56

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue4.89

Enterprise Value/Gross Profit33.13

Enterprise Value/Ebitda-1.55

Forecast

1Y Price Target

$11.38

Price Target Upside110.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityFoghorn Therapeutics has a cash runway extending into 2028, indicating financial stability for further development and research.

Innovative Drug DevelopmentFoghorn is developing novel inhibitors and degraders for oncology indications, including drugging historically 'undruggable' targets.

Strategic PartnershipThe strategic partnership with Eli Lilly de-risks Foghorn's program, defraying costs while positioning FHD-909 for a potential combination strategy in NSCLC.

Bears Say

Leadership ChangeThe resignation of Kristian Humer, CFO, is a significant loss and emphasizes the importance of the upcoming advancement decision from Lilly for FHD-909.

Potential Conflict Of InterestInvestors should be aware of a potential conflict of interest that could affect the objectivity of reports on Foghorn Therapeutics.

Foghorn Therapeutics News

3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy...

11d ago

FHTX

NUVL

Foghorn Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $11 price target The firm says...

11d ago

FHTX

Foghorn Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target. Lead asset FHD-909,...

26d ago

LLY

FHTX

Foghorn Therapeutics Appoints Interim CFO Jeff Sacher

An update from Foghorn Therapeutics ( ($FHTX) ) is now available. On December 3, 2025, Foghorn Therapeutics appointed...

25d ago

FHTX

Promising Developments and Strategic Partnerships Position Foghorn Therapeutics for Growth: A Buy Rating by Laura Prendergast

Laura Prendergast, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Foghorn Therapeutics (FHTX). Laura...

26d ago

FHTX

Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Foghorn Therapeutics, retaining the price target...

1M ago

FHTX

Foghorn Therapeutics Unveils Strategic Advancements with Lilly

Foghorn Therapeutics ( ($FHTX) ) has issued an announcement. In November 2025, Foghorn Therapeutics presented its strategic advancements,...

2M ago

FHTX

Foghorn Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target Published first on...

2M ago

FHTX

Foghorn Therapeutics Reports Q3 2025 Financial Results

Foghorn Therapeutics, Inc. ( ($FHTX) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

FHTX

Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

TD Cowen analyst Yaron Werber has reiterated their bullish stance on FHTX stock, giving a Buy rating on...

2M ago

FHTX

Foghorn Therapeutics CFO Kristian Humer Resigns

Foghorn Therapeutics ( ($FHTX) ) just unveiled an announcement. On October 31, 2025, Kristian Humer announced his resignation...

2M ago

FHTX

Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)

Reports Q3 revenue $8.153M, consensus $6.2M. “This quarter marked continued execution across our portfolio, reinforcing our leadership in...

2M ago

FHTX

Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating

Foghorn Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on October 30. Analyst Robert...

2M ago

FHTX

Foghorn Therapeutics: Advancements in Protein Degrader Programs and Strategic Partnerships Drive Buy Rating

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Foghorn Therapeutics today and set a price...

2M ago

FHTX

FHTX FAQ

What was Foghorn Therapeutics’s price range in the past 12 months?

Foghorn Therapeutics lowest stock price was $2.94 and its highest was $6.79 in the past 12 months.

What is Foghorn Therapeutics’s market cap?

Foghorn Therapeutics’s market cap is $305.38M.

When is Foghorn Therapeutics’s upcoming earnings report date?

Foghorn Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 66 days.

How were Foghorn Therapeutics’s earnings last quarter?

Foghorn Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.083.

Is Foghorn Therapeutics overvalued?

According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Foghorn Therapeutics pay dividends?

Foghorn Therapeutics does not currently pay dividends.

What is Foghorn Therapeutics’s EPS estimate?

Foghorn Therapeutics’s EPS estimate is -0.25.

How many shares outstanding does Foghorn Therapeutics have?

Foghorn Therapeutics has 56,551,290 shares outstanding.

What happened to Foghorn Therapeutics’s price movement after its last earnings report?

Foghorn Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went up 13.314%.

Which hedge fund is a major shareholder of Foghorn Therapeutics?

Currently, no hedge funds are holding shares in FHTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Foghorn Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics (FHTX) Earnings & Revenues

Historic Earnings Reports

FHTX Stock 12 Month Forecast

Average Price Target

$11.38

▲(110.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,5.138461538461539,5.876923076923077,6.615384615384615,7.353846153846154,8.092307692307692,8.830769230769231,9.569230769230769,10.307692307692307,11.046153846153846,11.784615384615385,12.523076923076923,13.26153846153846,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.936923076923077,5.4738461538461545,6.010769230769231,6.547692307692309,7.084615384615385,7.621538461538462,8.15846153846154,8.695384615384615,9.232307692307693,9.76923076923077,10.306153846153848,10.843076923076923,{"y":11.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.753846153846154,5.107692307692308,5.461538461538462,5.815384615384616,6.1692307692307695,6.523076923076923,6.876923076923077,7.230769230769231,7.584615384615384,7.938461538461539,8.292307692307691,8.646153846153846,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >